Weiner AB, Li EV, Desai AS, Press DJ, Schaeffer EM. Cause of death during prostate cancer survivorship: a contemporary, US population-based analysis. Cancer. 2021;127:2895–904.

Article  PubMed  Google Scholar 

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386–96.

Article  PubMed  Google Scholar 

Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203:1109–16.

Article  PubMed  Google Scholar 

Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sorensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144:1295–307.

Article  PubMed  PubMed Central  Google Scholar 

Hopmans SN, Duivenvoorden WCM, Werstuck GH, Pinthus J. GnRH antagonists associate with less weight gain and milder characteristics of the metabolic syndrome compared to orchiectomy and GnRH agonists in a preclinical mouse model. Urol Oncol. 2014;32:1126–34.

Article  CAS  PubMed  Google Scholar 

Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. Sci Rep. 2016;6:26220.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duivenvoorden W, Margel D, Subramony Gayathri V, Duceppe E, Yousef S, Naeim M, et al. Follicle-stimulating hormone exacerbates cardiovascular disease in the presence of low or castrate testosterone levels. JACC Basic Transl Sci. 2024;9:364–79.

Article  PubMed  Google Scholar 

Perrone V, Degli Esposti L, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag. 2020;16:393–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davey P, Kirby MG. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J Urol. 2021;39:307–15.

Article  CAS  PubMed  Google Scholar 

George G, Garmo H, Scailteux LM, Balusson F, De Coster G, De Schutter H, et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases. Int J Cancer. 2021;148:2203–11.

Article  CAS  PubMed  Google Scholar 

Crawford ED, Hafron JM, Debruyne F, Wallis C, Chang S, Garnick MB. Cardiovascular risk in prostate cancer patients using luteinizing hormone-releasing hormone agonists or a Gonadotropin-releasing hormone antagonist. J Urol. 2024;211:63–70.

Article  PubMed  Google Scholar 

Zhang KW, Reimers MA, Calaway AC, Fradley MG, Ponsky L, Garcia JA, et al. Cardiovascular events in men with prostate cancer receiving hormone therapy: an analysis of the FDA adverse event reporting system (FAERS). J Urol. 2021;206:613–22.

Article  PubMed  PubMed Central  Google Scholar 

Cone EB, Marchese M, Reese SW, Sun M, Nabi J, Kilbridge K, et al. Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. BJU Int. 2020;126:9–10.

Article  CAS  PubMed  Google Scholar 

Nelson AJ, Lopes RD, Hong H, Hua K, Slovin S, Tan S, et al. Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review. JACC CardioOncol. 2023;5:613–24.